Variety of eligible individuals: CDEC talked about the uncertainty in the number of patients with moderately serious to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some patients who will be labeled as acquiring gentle or